Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors



    VANCOUVER, April 14 /CNW/ - Medifocus Inc. (TSXV:MFS) announced that
positive clinical results when using the Company's proprietary focused heat
treatment prior to surgery for the treatment of early stage breast cancer
tumors, were presented during the Market Opening Ceremony of Medifocus at the
Toronto Stock Exchange on March 25, 2009 and also at the 19th National
Interdisciplinary Breast Center Conference held March 14-18, 2009 in Las
Vegas, Nevada. The patient data were obtained from a multi-center, randomized
clinical study to reduce cancer cells at the surgical margins, which
potentially can reduce either re-excision rates or second incision rates when
Medifocus's focused heat is delivered prior to surgery. This study was
conducted in the USA under an Investigational Device Exemption (IDE) issued by
the Food and Drug Administration (FDA). The data presented at the 2009
National Interdisciplinary Breast Center Conference represent the final
analysis of the clinical data for the focused heat treatment for early-stage
breast cancer. Dr. William C. Dooley, MD, at the University of Oklahoma,
Health Sciences Center, was the Principal Investigator of the
multi-institutional study that was conducted at 10 breast centers in the
United States and the United Kingdom.
    The primary treatment modality for the treatment of early stage breast
cancer is surgery. For early stage breast cancer, if the tumor is detected
early enough, and the tumor is small enough, then a breast conservation
surgery (BCS) known as lumpectomy could be offered. One of the biggest
concerns for lumpectomy is positive tumor margins, which normally will require
either re-excision or second incision to remove the remaining cancer cells. In
addition, clinical studies indicate that if the surgery is performed and the
margin is positive with cancer cells, then there is an estimated 500% increase
in the chance for recurrence of the breast cancer compared to when the margins
are negative. The reported clinical trial results demonstrated that when
Medifocus's focused heat therapy alone was delivered prior to surgery, 0 of 34
(0%) of the tumors removed had positive margins whereas in the surgical arm
without receiving the focused heat treatment, 4 of 41 or almost 10% had
positive margins.
    This study, along with the positive clinical efficacy results of another
randomized study for the treatment of large breast cancer tumors that
Medifocus reported last week, demonstrates that Medifocus's focused heat
technology can potentially treat the majority of all localized and invasive
breast cancer tumors detected. The study reported last week demonstrated that
when Medifocus's focused heat was added to the standard of care (SOC)
neo-adjuvant chemotherapy in the treatment of large breast cancer tumors,
tumor shrinkage was increased by an additional 50% over that induced by (SOC)
chemotherapy alone.
    The treatment goal of the Medifocus study on early stage breast cancer is
to demonstrate that focused heat treatment delivered prior to surgery can
improve surgical outcomes and decrease the need for re-excisions or a second
incision which can improve cosmesis and may reduce recurrent rates of the
breast cancer.

    About Medifocus
    Medifocus owns a patented microwave focusing technology (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures,
to treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger
the targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the
Massachusetts Institute of Technology, Medifocus has further refined the
precision of the microwave focusing and control ability and developed a
commercial system dedicated exclusively for the treatment of Breast Cancer.
Please visit www.medifocusinc.com for more details.

    Forward-Looking Statements and Information

    This News Release contains forward-looking statements which may not be
based on historical fact. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. These factors should be considered carefully and readers are
cautioned not to place undue reliance on such forward-looking statements. The
company disclaims any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments.

    %SEDAR: 00023463E




For further information:

For further information: Gilbert Chan, NAI Interactive Ltd.,
gil@na-investor.com, (604) 488-8878, 1-866-833-5517; John Mon, Medifocus Inc.,
jmon@medifocusinc.com, Telephone (410) 290-5734

Organization Profile

MEDIFOCUS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890